Alnylam to webcast conference call discussing fourth quarter and full year 2022 financial results
Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that it will report financial results for the fourth quarter and year ending december 31, 2022 on thursday, february 23, 2023, before the u.s. financial markets open. management will provide an update on the company and discuss fourth quarter and year-end 2022 results as well as expectations for the future via conference call on thursday, february 23, 2023 at 8:30 am et. to access the call, please register online at https://register.vevent.com/register/bi050ad56309204f0a836ec037dd396473. participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. a replay of the call will be available two hours after the call and archived on the same web page for six months. a live audio webcast of the call will be available on the investors section of the company’s website at www.alnylam.com/events. an archived webcast will be available on the alnylam website approximately two hours after the event. about alnylam pharmaceuticals alnylam pharmaceuticals (nasdaq: alny) has led the translation of rna interference (rnai) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. based on nobel prize-winning science, rnai therapeutics represent a powerful, clinically validated approach yielding transformative medicines. since its founding 20 years ago, alnylam has led the rnai revolution and continues to deliver on a bold vision to turn scientific possibility into reality. alnylam’s commercial rnai therapeutic products are onpattro® (patisiran), amvuttra® (vutrisiran), givlaari® (givosiran), oxlumo® (lumasiran), and leqvio® (inclisiran), which is being developed and commercialized by alnylam’s partner, novartis. alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. alnylam is executing on its “alnylam p5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. alnylam is headquartered in cambridge, ma. for more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on twitter at @alnylam, on linkedin, or on instagram.
ALNY Ratings Summary
ALNY Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission